Discover the Latest Trends with New Arrivals at WSM Apparel
At WSM Apparel, our New Arrivals collection is...
Future of Pharmaceuticals: AI in Drug Discovery Market to Expand Rapidly Through 2030
Meticulous Research® has published a comprehensive report on the growing AI in Drug Discovery Market, providing insights into key trends, growth drivers, and competitive analysis across various segments. The global market is projected to reach $8.95 billion by 2030, with a compound annual growth rate (CAGR) of 27.2% from 2024 to 2030.Download Sample Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5429
Artificial intelligence (AI) is rapidly transforming industries, and the pharmaceutical sector is no exception. The use of AI in drug discovery is revolutionizing the way new therapies are developed, significantly reducing the time and cost associated with bringing new drugs to market. According to Meticulous Research®, the AI in drug discovery market is poised for substantial growth in the coming years, driven by several key factors, including the rising incidence of chronic diseases, the growing need to reduce turnaround times in drug development, and the increasing applications of AI technologies in healthcare.
Market Growth Drivers
The AI in drug discovery market is expected to experience significant growth due to the rising focus on reducing drug development time and costs. Traditional drug discovery processes are often slow, labor-intensive, and costly. AI technologies, such as machine learning (ML) and deep learning, are helping researchers analyze large datasets more quickly and accurately, identifying potential drug candidates faster than ever before. The increasing incidence of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders is further driving the demand for AI-based drug discovery solutions.
Additionally, advancements in AI technologies, particularly in the healthcare sector, are creating new opportunities for pharmaceutical companies to leverage AI for drug discovery. The growing number of AI start-ups and the rising investments in AI-based research and development (R&D) are also contributing to the market’s expansion. Many pharmaceutical companies and research organizations are increasingly adopting AI-powered platforms to streamline their drug discovery processes, reduce costs, and accelerate the development of new therapies.
Market Segmentation
The global AI in drug discovery market is segmented based on offering, deployment mode, application, therapeutic area, end user, and geography.
Browse In Depth: https://www.meticulousresearch.com/product/artificial-intelligence-in-drug-discovery-market-5429
Offering
In terms of offerings, the AI in drug discovery market is divided into software and services. In 2024, the software segment is expected to account for the largest market share. AI software solutions are increasingly being adopted to reduce the time and costs involved in drug discovery. These software platforms are typically offered through licensed, subscription-based, and software-as-a-service (SaaS) models, providing recurring revenue for vendors. The high adoption of AI software in drug discovery is driven by its ability to automate various stages of drug development, from target identification to clinical testing.
Deployment Mode
By deployment mode, the market is categorized into on-premises and cloud-based solutions. The cloud and web-based segment is projected to witness the fastest growth during the forecast period. Cloud platforms offer several advantages, including scalability, cost-effectiveness, and accessibility. Cloud-based solutions are particularly beneficial for storing and analyzing large datasets, which are common in drug discovery. Pharmaceutical companies are increasingly opting for cloud-based AI platforms to manage and process the vast amounts of data generated during drug discovery, driving the growth of this segment.
Application
Based on application, the AI in drug discovery market is segmented into target discovery and validation, lead compound identification, de novo design and drug optimization, and preclinical and clinical testing. The lead compound identification segment is expected to hold the largest market share in 2024. Lead compound identification is a crucial step in drug discovery, as it involves finding molecules with the potential to become therapeutic drugs. AI technologies are increasingly being used at this stage to identify promising compounds more efficiently, reducing the time required to bring new drugs to market.
Therapeutic Area
The AI in drug discovery market is further segmented by therapeutic area, including oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others. In 2024, the oncology segment is projected to account for the largest share of the market. The rising prevalence of cancer globally, coupled with the growing focus on developing AI-driven oncology therapies, is driving the demand for AI in drug discovery for cancer treatments. According to the International Agency for Research on Cancer, nearly 19.3 million new cancer cases were reported globally in 2020, highlighting the need for more effective and efficient cancer therapies. AI technologies are playing a critical role in accelerating the discovery of novel cancer treatments, contributing to the growth of the oncology segment.
End User
The end user segment of the AI in drug discovery market includes pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), and academic and research institutes. Pharmaceutical and biopharmaceutical companies are expected to dominate the market in 2024, accounting for the largest share. These companies are investing heavily in AI technologies to enhance their drug discovery capabilities, particularly in the development of oncology therapies. The adoption of AI in pharmaceutical R&D is also driven by the need to streamline drug discovery processes and reduce costs.
Geographical Analysis
Geographically, the AI in drug discovery market is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the global market in 2024, with the U.S. holding the largest share in the region. The North American market is driven by significant public and private investments in drug discovery, as well as the high adoption of AI solutions in the pharmaceutical industry. The presence of major AI and pharmaceutical companies, such as Microsoft Corporation, Pfizer Inc., and Abbott Laboratories, also supports the growth of the market in North America.
Europe is the second-largest market for AI in drug discovery, with countries such as Germany, France, and the U.K. playing a key role in the region’s growth. The growing focus on AI-driven drug discovery and the rising investments in R&D are contributing to the expansion of the European market.
Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by the increasing adoption of AI technologies in drug discovery and the rising focus on improving healthcare infrastructure in countries like China, Japan, and India. The growing number of AI start-ups and rising government investments in healthcare R&D are also contributing to the market’s growth in the region.
Quick Buy – Artificial Intelligence in Drug Discovery Market – Global Opportunity Analysis and Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/74258841
Key Market Players
The global AI in drug discovery market is highly competitive, with several key players operating in the space. Some of the prominent companies in the market include Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrödinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea). These companies are focusing on developing advanced AI platforms and forging partnerships with pharmaceutical companies to expand their presence in the AI in drug discovery market.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post